Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02141490 · ClinicalTrials.gov registry record · Phase 2

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
43
Enrollment target

NCT02141490: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT02141490 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02141490, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target

Study Summary

Background: People with prostate, bladder, or kidney cancer often have their cancer spread (metastasize) to lymph nodes. It is important for your doctor to know if this has occurred but currently it can be hard to determine if this has occurred on standard imaging studies like computed tomography (CT) or magnetic resonance imaging (MRI). This study uses an agent called Ferumoxytol to identify lymph nodes that might be involved by cancer. Objective: \- To see how well Ferumoxytol can detect lymph node metastases in patients with prostate, bladder, or kidney cancer. Eligibility: -Adults over age 18 with prostate, bladder, or kidney cancer with lymph node involvement. Design: * Participants will be screened with a medical history. * Participants will have blood drawn and a physical exam. Their vital signs will be measured. They will answer questions about their health and current medications. * Participants should not have a history of iron overload or have an allergy to Ferumoxytol. * Participants will have a magnetic resonance imaging (MRI) scan. The scanner is a metal cylinder with a strong magnetic field. Participants will lie on a table that slides in and out of the scanner. They will have a standard sensor, known as a coil, wrapped around their abdomen to improve the scan. This is like a small blanket with wiring inside. Participants will need to lie still on the scanning table for about 1 hour. * Participants will have an ultrasound. This uses harmless sound waves to provide pictures of organs or tissues inside the body. * Participants will receive an injection of Ferumoxytol through an intravenous line. A very thin plastic tube will be inserted into a vein in order to inject the agent. * Participants will have another MRI and ultrasound 24 and 48 hours after injection. * The study will follow participants medical course for at least 1 year.

Primary Outcome

Visible nodes were quantified with manually contoured regions of interest on axial T2\*W MRI to obtain the mean signal intensity (SInode). The SI of the visible lymph node was normalized using the mean SI of the adjacent muscle tissue on the same slice (SImuscle). The following equation was used to obtain the normalized SI from the lymph node (SInormal): SInormal=SInode/SImuscle. The calculation formula was 100% \* ((SInormal(24hrs)- SInormal(baseline))/ SInormal(baseline)).This image processing

Interventions

  • DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)
  • DRUG Ferumoxytol

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2014-05-15
Est. Completion 2018-11-20
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT02141490 record still lists

NCT02141490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT02141490 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02141490 about?

NCT02141490 is a clinical study titled "Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers". Background: People with prostate, bladder, or kidney cancer often have their cancer spread (metastasize) to lymph nodes. It is important for your doctor to know if this has occurred but currently it can be hard to determine if this has occurred on standard imaging studies like computed tomography (...

What is the current status of trial NCT02141490?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-05-15. Estimated completion is 2018-11-20.

What interventions are being tested in trial NCT02141490?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Ferumoxytol (DRUG).

Who is sponsoring clinical trial NCT02141490?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02141490's enrollment target sits among peer trials

43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02141490, the US trial registry maintained by the National Library of Medicine. NCT02141490 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.